Clinical trials: Locally Advanced, Recurrent or Metastatic Malignancies
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03428802
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Rutgers, The State University of New Jersey
Stomatitis
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal…
- Trial name
- TROPION-SWISH (NCT07357597)
- Testing
- Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd)
- Where
- 41 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Triple-negative Breast Cancer
A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
To evaluate the clinical efficacy and safety of oral all-trans retinoic acid in combination with toripalimab in patients with locally advanced, recurrent, or metastatic triple-negative breast cancer who had failed second-line and…
- Trial name
- NCT06371274
- Testing
- ATRA, Toripalimab
- Where
- China
- Volunteers
- 29 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Esophageal Cancer, Gastric Cancer
Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have locally…
- Trial name
- NCT00005876
- Testing
- rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Fallopian Tube Cancer, Female Reproductive Cancer
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
This phase II trial is studying how well ziv-aflibercept works in treating patients with locally advanced, unresectable or metastatic gynecologic soft tissue sarcoma.
- Conditions
- Fallopian Tube Cancer, Female Reproductive Cancer, Ovarian Carcinosarcoma, Ovarian Sarcoma
- Trial name
- NCT00390234
- Testing
- ziv-aflibercept
- Where
- 16 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
This randomized phase III trial studies exemestane and entinostat to see how well they work compared to exemestane alone in treating patients with hormone receptor-positive breast cancer that has spread to nearby tissue or lymph…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative
- Trial name
- NCT02115282
- Testing
- Biospecimen Collection, Computed Tomography, Entinostat
- Where
- 653 sites in United States, South Africa
- Volunteers
- 608 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
This is a randomized, controlled, multi-center, open trial, unresectable locally advanced or metastatic esophageal squamous cell carcinoma patients that failed at least second-line treatment and overexpressed EGFR were enrolled…
- Trial name
- NCT04415853
- Testing
- Lerotinib, Irinotecan/Tegafur
- Where
- China
- Volunteers
- 416 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
This phase II trial compares the effect of amivantamab and hyaluronidase to cetuximab for the treatment of skin (cutaneous) squamous cell carcinoma that has come back after a period of improvement and has not spread to other…
- Trial name
- NCT07042295
- Testing
- Amivantamab and Recombinant Human Hyaluronidase, Biospecimen Collection, Cetuximab
- Where
- 55 sites in United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Hormone Therapy in Treating Women With Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using arzoxifene hydrochloride may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00003428
- Testing
- arzoxifene hydrochloride
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Cancer
Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer
This study is an open-label, multicenter, phase II study to evaluate the efficacy and safety of DP303c injection in patients with HER2-positive advanced or metastatic gastric cancer.
- Trial name
- NCT04826107
- Testing
- DP303c treatment, DP303c treatment（second-line of HER2-positive）, DP303c treatment （third-line of HER2-positive）
- Volunteers
- 196 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00075647
- Testing
- temsirolimus, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma, Advanced Urothelial Carcinoma
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
This is a multicenter, open-label, Phase II clinical trial to evaluate the efficacy and safety of Trastuzumab Rezetecan (SHR-A1811) or in combination with Adebrelimab (SHR-1316) for HER2-expressing locally advanced or metastatic…
- Conditions
- Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma Recurrent
- Trial name
- TRAIN-UC-01 (NCT07241793)
- Testing
- Adebrelimab, Trastuzumab Rezetecan
- Where
- 6 sites in China
- Volunteers
- 96 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
Phase I trial to study the effectiveness of ZD 1839 combined with irinotecan, leucovorin, and fluorouracil in treating patients who have locally advanced, locally recurrent, or metastatic colorectal cancer.
- Trial name
- NCT00026364
- Testing
- fluorouracil, gefitinib, irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Triple Negative Breast Cancer
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
This is a Phase III, randomized, open-label, 2-arm, multicentre, international study assessing the efficacy and safety of FDA018-ADC compared with Investigator's Choice Chemotherapy(ICC) in participants with locally recurrent…
- Trial name
- NCT06519370
- Testing
- FDA018-ADC, Eribulin, Capecitabine
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Recurrent Breast Cancer, Stage IV Breast Cancer
Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
This phase II trial is to see if combining bevacizumab with docetaxel works in treating women who have locally advanced or metastatic breast cancer.
- Trial name
- NCT00055861
- Testing
- bevacizumab, docetaxel, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Transitional Cell Carcinoma of Bladder
PF-03446962 in Relapsed or Refractory Urothelial Cancer
Salvage chemotherapy for advanced urothelial cancer (UC) yields suboptimal response rates of 15-40%, a median progression-free survival of 2-4 months and a median overall survival of 6 months.
- Trial name
- NCT01620970
- Testing
- PF03446962
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Sarcoma
Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the tumor.
- Trial name
- NCT00052390
- Testing
- bevacizumab, doxorubicin hydrochloride
- Where
- 3 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer, PD-L1 Positive
A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.
A prospective, controlled Phase II clinical study on the efficacy and safety of the combination of limertinib and bevacizumab versus limertinib monotherapy as first - line treatment for locally advanced or recurrent metastatic…
- Trial name
- LIBRA (NCT06982924)
- Testing
- Limertinib+bevacizumab, Limertinib
- Volunteers
- 136 people
- Sponsor
- Shanghai Chest Hospital
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health